Pub Date : 2025-10-18DOI: 10.1016/j.endien.2025.501639
María Asunción Martínez-Brocca , Virginia Bellido , Roque Cardona-Hernandez , Luis Castaño , Ignacio Conget , Alberto Fernández , Ana Lucía Gómez Gila , Isabel Leiva-Gea , Dídac Mauricio
Type 1 diabetes (T1D) is an autoimmune disease whose late diagnosis can lead to serious complications such as diabetic ketoacidosis, especially in children. The presence of specific autoantibodies allows for the identification of a presymptomatic phase, opening the door to screening strategies targeting populations at high genetic risk, such as first-degree relatives. This document presents the consensus recommendations of the Spanish Diabetes Society (SED), the Spanish Society of Endocrinology and Nutrition (SEEN) and the Spanish Society of Paediatric Endocrinology (SEEP) on the screening, staging and monitoring of T1D in preclinical stages. Early identification of the disease will enable a personalised approach to be established, promote health education and, eventually, consider therapeutic interventions that may delay progression to the symptomatic phase. This consensus seeks to establish a common framework for clinical action based on the available evidence, with clear recommendations for its proper implementation.
{"title":"Executive summary. Screening, staging and follow-up of type 1 diabetes in preclinical stages: Consensus of the scientific societies SED, SEEN and SEEP","authors":"María Asunción Martínez-Brocca , Virginia Bellido , Roque Cardona-Hernandez , Luis Castaño , Ignacio Conget , Alberto Fernández , Ana Lucía Gómez Gila , Isabel Leiva-Gea , Dídac Mauricio","doi":"10.1016/j.endien.2025.501639","DOIUrl":"10.1016/j.endien.2025.501639","url":null,"abstract":"<div><div>Type 1 diabetes (T1D) is an autoimmune disease whose late diagnosis can lead to serious complications such as diabetic ketoacidosis, especially in children. The presence of specific autoantibodies allows for the identification of a presymptomatic phase, opening the door to screening strategies targeting populations at high genetic risk, such as first-degree relatives. This document presents the consensus recommendations of the Spanish Diabetes Society (SED), the Spanish Society of Endocrinology and Nutrition (SEEN) and the Spanish Society of Paediatric Endocrinology (SEEP) on the screening, staging and monitoring of T1D in preclinical stages. Early identification of the disease will enable a personalised approach to be established, promote health education and, eventually, consider therapeutic interventions that may delay progression to the symptomatic phase. This consensus seeks to establish a common framework for clinical action based on the available evidence, with clear recommendations for its proper implementation.</div></div>","PeriodicalId":48650,"journal":{"name":"Endocrinologia Diabetes Y Nutricion","volume":"72 9","pages":"Article 501639"},"PeriodicalIF":1.8,"publicationDate":"2025-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145330442","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-01DOI: 10.1016/j.endien.2025.501596
María Díaz-Tobarra , Sara Subirats Bort , Ignacio Peña Saiz de Aja , Gonzalo Villar García , Encarnación Lag Asturiano
{"title":"Coexistance of metastatic papillary thyroid microcarcinoma and medullary thyroid carcinoma in MEN 2B. Case report and literature review","authors":"María Díaz-Tobarra , Sara Subirats Bort , Ignacio Peña Saiz de Aja , Gonzalo Villar García , Encarnación Lag Asturiano","doi":"10.1016/j.endien.2025.501596","DOIUrl":"10.1016/j.endien.2025.501596","url":null,"abstract":"","PeriodicalId":48650,"journal":{"name":"Endocrinologia Diabetes Y Nutricion","volume":"72 8","pages":"Article 501596"},"PeriodicalIF":1.8,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145058792","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
This study aimed to assess serum Neuromedin U (NmU) levels in patients with Type 1 (T1DM) and Type 2 diabetes mellitus (T2DM) vs healthy controls and evaluate the correlation between NmU and body mass index (BMI).
Research design and methods
We conducted a cross-sectional study with 134 participants: 45 with T1DM, 49 with T2DM, and 40 healthy controls. Serum NmU levels were measured using enzyme-linked immunosorbent assay (ELISA), and the correlation with BMI was assessed.
Results
NmU levels were not significantly different between diabetic patients and healthy controls. No significant correlation was observed between NmU and BMI in T1DM or T2DM groups. However, the healthy control group found a significant inverse correlation between NmU and BMI (rho = −0.373, p < 0.05).
Conclusions
NmU may not be a direct biomarker for diabetes, but its significant correlation with BMI in healthy individuals suggests a potential role in metabolic regulation. This is the first study ever conducted to compare NmU levels across diabetic subtypes, offering novel insights into the role of in metabolic homeostasis.
目的比较1型糖尿病（T1DM）和2型糖尿病（T2DM）患者与健康对照者血清神经medin U （NmU）水平，并评价NmU与体重指数（BMI）的相关性。研究设计和方法我们对134名参与者进行了横断面研究：45名1型糖尿病患者，49名2型糖尿病患者，40名健康对照。采用酶联免疫吸附试验（ELISA）测定血清NmU水平，并评估与BMI的相关性。结果糖尿病患者血清snmu水平与健康对照组无显著差异。T1DM组和T2DM组NmU与BMI无显著相关性。而健康对照组NmU与BMI呈显著负相关（rho = - 0.373, p < 0.05）。结论snmu可能不是糖尿病的直接生物标志物，但其与健康个体BMI的显著相关性提示其在代谢调节中可能发挥作用。这是有史以来第一个比较糖尿病亚型中NmU水平的研究，为其在代谢稳态中的作用提供了新的见解。
{"title":"Neuromedin U and BMI correlation in T1DM and T2DM vs healthy controls: A comparative study","authors":"Yasemin Çalışkan , Emre Sarandöl , Nizameddin Koca","doi":"10.1016/j.endien.2025.501631","DOIUrl":"10.1016/j.endien.2025.501631","url":null,"abstract":"<div><h3>Objective</h3><div>This study aimed to assess serum Neuromedin U (NmU) levels in patients with Type 1 (T1DM) and Type 2 diabetes mellitus (T2DM) vs healthy controls and evaluate the correlation between NmU and body mass index (BMI).</div></div><div><h3>Research design and methods</h3><div>We conducted a cross-sectional study with 134 participants: 45 with T1DM, 49 with T2DM, and 40 healthy controls. Serum NmU levels were measured using enzyme-linked immunosorbent assay (ELISA), and the correlation with BMI was assessed.</div></div><div><h3>Results</h3><div>NmU levels were not significantly different between diabetic patients and healthy controls. No significant correlation was observed between NmU and BMI in T1DM or T2DM groups. However, the healthy control group found a significant inverse correlation between NmU and BMI (rho<!--> <!-->=<!--> <!-->−0.373, <em>p</em> <!--><<!--> <!-->0.05).</div></div><div><h3>Conclusions</h3><div>NmU may not be a direct biomarker for diabetes, but its significant correlation with BMI in healthy individuals suggests a potential role in metabolic regulation. This is the first study ever conducted to compare NmU levels across diabetic subtypes, offering novel insights into the role of in metabolic homeostasis.</div></div>","PeriodicalId":48650,"journal":{"name":"Endocrinologia Diabetes Y Nutricion","volume":"72 8","pages":"Article 501631"},"PeriodicalIF":1.8,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145236393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-01DOI: 10.1016/j.endien.2025.501578
Mohammed Hamsho , Yazan Ranneh , Abdulmannan Fadel
Background
Polycystic ovarian syndrome (PCOS) has been treated recently with chromium supplementations. However, it is unknown if this dietary supplement has similar effect to metformin.
Aim
The aim of this study was to investigate the efficacy of chromium supplementation in women with PCOS.
Methods
A meta-analysis was conducted using relevant articles obtained from searches of PubMed, Scopus, Embase, and Google Scholar. The mean difference and standardized mean difference were employed to determine the effect size for biochemical parameters.
Results
A total of 10 randomized controlled trials involving 683 women were included in the analysis. The results indicated that chromium supplementation, as vs a placebo, significantly decreased fasting blood insulin (P = 0.01), triglyceride (P < 0.00001), total cholesterol (P < 0.00001), very low-density lipoprotein (P < 0.00001), low-density lipoprotein (P = 0.0003), high sensitivity C-reactive protein (P = 0.02), malondialdehyde (P = 0.007), follicle stimulating hormone (P = 0.0007), and prolactin (P = 0.01), and increased the Quantitative Insulin Sensitivity Check Index (P = 0.02), total antioxidant capacity (P < 0.0001), and ovulation incidence (P = 0.001). Chromium supplementation was also found to be more effective than metformin in reducing HOMA-IR (P < 0.00001), and luteinizing hormone (P = 0.04).
Conclusion
Chromium picolinate supplementation at a dosage of 200 μg may provide benefits similar to metformin with regard to FBG, FBI, ovulation, and pregnancy incidence, with fewer side effects in patients with PCOS. Further experiments are still required to draw effective dietary guidelines related to chromium.
{"title":"Therapeutic effects of chromium supplementation on women with polycystic ovarian syndrome: A systematic review and meta-analysis","authors":"Mohammed Hamsho , Yazan Ranneh , Abdulmannan Fadel","doi":"10.1016/j.endien.2025.501578","DOIUrl":"10.1016/j.endien.2025.501578","url":null,"abstract":"<div><h3>Background</h3><div>Polycystic ovarian syndrome (PCOS) has been treated recently with chromium supplementations. However, it is unknown if this dietary supplement has similar effect to metformin.</div></div><div><h3>Aim</h3><div>The aim of this study was to investigate the efficacy of chromium supplementation in women with PCOS.</div></div><div><h3>Methods</h3><div>A meta-analysis was conducted using relevant articles obtained from searches of PubMed, Scopus, Embase, and Google Scholar. The mean difference and standardized mean difference were employed to determine the effect size for biochemical parameters.</div></div><div><h3>Results</h3><div>A total of 10 randomized controlled trials involving 683 women were included in the analysis. The results indicated that chromium supplementation, as vs a placebo, significantly decreased fasting blood insulin (<em>P</em> <!-->=<!--> <!-->0.01), triglyceride (<em>P</em> <!--><<!--> <!-->0.00001), total cholesterol (<em>P</em> <!--><<!--> <!-->0.00001), very low-density lipoprotein (<em>P</em> <!--><<!--> <!-->0.00001), low-density lipoprotein (<em>P</em> <!-->=<!--> <!-->0.0003), high sensitivity C-reactive protein (<em>P</em> <!-->=<!--> <!-->0.02), malondialdehyde (<em>P</em> <!-->=<!--> <!-->0.007), follicle stimulating hormone (<em>P</em> <!-->=<!--> <!-->0.0007), and prolactin (<em>P</em> <!-->=<!--> <!-->0.01), and increased the Quantitative Insulin Sensitivity Check Index (<em>P</em> <!-->=<!--> <!-->0.02), total antioxidant capacity (<em>P</em> <!--><<!--> <!-->0.0001), and ovulation incidence (<em>P</em> <!-->=<!--> <!-->0.001). Chromium supplementation was also found to be more effective than metformin in reducing HOMA-IR (<em>P</em> <!--><<!--> <!-->0.00001), and luteinizing hormone (<em>P</em> <!-->=<!--> <!-->0.04).</div></div><div><h3>Conclusion</h3><div>Chromium picolinate supplementation at a dosage of 200<!--> <!-->μg may provide benefits similar to metformin with regard to FBG, FBI, ovulation, and pregnancy incidence, with fewer side effects in patients with PCOS. Further experiments are still required to draw effective dietary guidelines related to chromium.</div></div>","PeriodicalId":48650,"journal":{"name":"Endocrinologia Diabetes Y Nutricion","volume":"72 8","pages":"Article 501578"},"PeriodicalIF":1.8,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145236396","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-01DOI: 10.1016/j.endien.2025.501635
Fidel Jesús Enciso Izquierdo , María José Amaya García , Paula Gómez Turégano , María Luengo Andrada , Ana Alejandra Cordero Vaquero , José Antonio Lucas Gamero , Sergio Garrido Domínguez , Irene Álvarez Reyes
Introduction
The active insulin time (AIT) is an adjustable parameter of the MiniMed™ 780G (MM780G) system. We analyze glucose outcomes and patient perception at different AIT settings.
Method
We conducted a quasi-experimental study on type 1 diabetes mellitus patients treated with MM780G, seen consecutively in our center. AIT was set at 2, 3 and 4 h consecutively, during a 2-week period each. Glucose metrics, insulin delivery and a questionnaire about patient perception were evaluated. At the end, results were discussed with the patient and the most appropriate AIT was agreed upon.
Results
A total of 58 users were included, aged 18–65 years, 58.6% of whom were women. At baseline, 2-h AIT was set in 6.70% of the patients, >2-h AIT and ≤3-h AIT in 24.67%, >3-h AIT and ≤4-h AIT in 58.62%, and >4-h AIT in 10.34%. Under the 2-h AIT, TIR increased by 2.28% and 6.35% vs 3- and 4-h AIT, respectively. The auto-correction boluses percentage was 21.19% at 2-h AIT, 16.90% at 3-h AIT and 14.40% at 4-h AIT.
A total of 41.4% of the users considered that 3 h was the AIT that most met their needs and 43.1% felt safer and less vulnerable to hypoglycemia at this setting. After trying on different AIT durations, 2 h increased from 6.7% of participants to 62%.
Conclusion
At 2-h AIT, the system delivers more auto-correction insulin and improves TIR vs 3- and 4-h AIT. Patients feel safer and less susceptible to hypoglycemia at 3-h AIT, but 2 out of 3 would rather choose the 2-h AIT after knowing glycemic outcomes.
胰岛素活性时间（AIT）是MiniMed™780G （MM780G）系统的可调参数。我们分析了不同AIT设置下的血糖结果和患者感知。方法对1型糖尿病患者进行MM780G治疗的准实验研究，在本中心连续观察。AIT分别于2、3、4小时连续设置，每次2周。评估血糖指标、胰岛素输送和患者感知问卷。最后，与患者讨论结果并商定最合适的AIT。结果共纳入58例患者，年龄18 ~ 65岁，其中58.6%为女性。基线时，6.70%的患者有2小时AIT， 24.67%的患者有2小时AIT和≤3小时AIT， 58.62%的患者有3小时AIT和≤4小时AIT， 10.34%的患者有4小时AIT。经2 h处理后，TIR比3 h和4 h分别提高了2.28%和6.35%。2 h自动校正丸率为21.19%，3 h为16.90%，4 h为14.40%。共有41.4%的用户认为3小时是最能满足他们需求的AIT， 43.1%的用户认为在这个设置下更安全，更不容易发生低血糖。在尝试不同的AIT持续时间后，2小时的参与者从6.7%增加到62%。结论与3 h和4 h AIT相比，2 h AIT系统可提供更多的自动校正胰岛素，提高TIR。患者感觉3小时AIT更安全，更不易发生低血糖，但3人中有2人在了解血糖结果后更愿意选择2小时AIT。
{"title":"Active insulin time setting in MiniMed™ 780G: Impact on glucose control and patient perception","authors":"Fidel Jesús Enciso Izquierdo , María José Amaya García , Paula Gómez Turégano , María Luengo Andrada , Ana Alejandra Cordero Vaquero , José Antonio Lucas Gamero , Sergio Garrido Domínguez , Irene Álvarez Reyes","doi":"10.1016/j.endien.2025.501635","DOIUrl":"10.1016/j.endien.2025.501635","url":null,"abstract":"<div><h3>Introduction</h3><div>The active insulin time (AIT) is an adjustable parameter of the MiniMed™ 780G (MM780G) system. We analyze glucose outcomes and patient perception at different AIT settings.</div></div><div><h3>Method</h3><div>We conducted a quasi-experimental study on type 1 diabetes mellitus patients treated with MM780G, seen consecutively in our center. AIT was set at 2, 3 and 4<!--> <!-->h consecutively, during a 2-week period each. Glucose metrics, insulin delivery and a questionnaire about patient perception were evaluated. At the end, results were discussed with the patient and the most appropriate AIT was agreed upon.</div></div><div><h3>Results</h3><div>A total of 58 users were included, aged 18–65 years, 58.6% of whom were women. At baseline, 2-h AIT was set in 6.70% of the patients, >2-h AIT and ≤3-h AIT in 24.67%, >3-h AIT and ≤4-h AIT in 58.62%, and >4-h AIT in 10.34%. Under the 2-h AIT, TIR increased by 2.28% and 6.35% vs 3- and 4-h AIT, respectively. The auto-correction boluses percentage was 21.19% at 2-h AIT, 16.90% at 3-h AIT and 14.40% at 4-h AIT.</div><div>A total of 41.4% of the users considered that 3<!--> <!-->h was the AIT that most met their needs and 43.1% felt safer and less vulnerable to hypoglycemia at this setting. After trying on different AIT durations, 2<!--> <!-->h increased from 6.7% of participants to 62%.</div></div><div><h3>Conclusion</h3><div>At 2-h AIT, the system delivers more auto-correction insulin and improves TIR vs 3- and 4-h AIT. Patients feel safer and less susceptible to hypoglycemia at 3-h AIT, but 2 out of 3 would rather choose the 2-h AIT after knowing glycemic outcomes.</div></div>","PeriodicalId":48650,"journal":{"name":"Endocrinologia Diabetes Y Nutricion","volume":"72 8","pages":"Article 501635"},"PeriodicalIF":1.8,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145236394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-01DOI: 10.1016/j.endien.2025.5015616
Fernando Guerrero-Pérez
{"title":"Analysis of pituitary dysfunction in patients with hypothalamic-pituitary axis disorders not associated with pituitary adenomas","authors":"Fernando Guerrero-Pérez","doi":"10.1016/j.endien.2025.5015616","DOIUrl":"10.1016/j.endien.2025.5015616","url":null,"abstract":"","PeriodicalId":48650,"journal":{"name":"Endocrinologia Diabetes Y Nutricion","volume":"72 8","pages":"Article 5015616"},"PeriodicalIF":1.8,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145056058","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-01DOI: 10.1016/j.endien.2025.501593
Carmen Martínez del Río , Isabel Cuellar-Flores , Diego López de Lara , Raúl Castañeda-Vozmediano , María Miguélez González , Alicia Gaitero Pérez , Olga Pérez Rodríguez , Adrián García Ron
Introduction
Recent studies suggest a higher prevalence of attention-deficit hyperactivity disorder (ADHD) in transgender individuals compared to the general population. However, no studies have been conducted in the Spanish population, and most focus on individuals with a prior ADHD diagnosis rather than screening for the disorder.
Materials and methods
This is a single-center, cross-sectional observational study assessing the risk of ADHD in transgender adolescents and young adults compared to cisgender individuals using the World Health Organization's (WHO) Adult ADHD Self-Report Scale (ASRS-V1.1). Additionally, previous mental health diagnoses and experiences of discrimination are analyzed in both groups.
Results
Transgender youth scored higher on the short-form scale, indicating a greater risk of ADHD, as well as on the hyperactivity/impulsivity subscale. A significant association was also found between experiences of discrimination and a prior diagnosis of depression.
Conclusions
The ASRS-V1.1 scale may be useful for ADHD screening in transgender individuals; however, further studies are needed to confirm these findings. Risk factors for neurodevelopmental and anxiety-depressive disorders may differ in the transgender population.
{"title":"Attention deficit hyperactivity disorder risk, mental health diagnoses and experience of discrimination in transgender adolescents and youth","authors":"Carmen Martínez del Río , Isabel Cuellar-Flores , Diego López de Lara , Raúl Castañeda-Vozmediano , María Miguélez González , Alicia Gaitero Pérez , Olga Pérez Rodríguez , Adrián García Ron","doi":"10.1016/j.endien.2025.501593","DOIUrl":"10.1016/j.endien.2025.501593","url":null,"abstract":"<div><h3>Introduction</h3><div>Recent studies suggest a higher prevalence of attention-deficit hyperactivity disorder (ADHD) in transgender individuals compared to the general population. However, no studies have been conducted in the Spanish population, and most focus on individuals with a prior ADHD diagnosis rather than screening for the disorder.</div></div><div><h3>Materials and methods</h3><div>This is a single-center, cross-sectional observational study assessing the risk of ADHD in transgender adolescents and young adults compared to cisgender individuals using the World Health Organization's (WHO) Adult ADHD Self-Report Scale (ASRS-V1.1). Additionally, previous mental health diagnoses and experiences of discrimination are analyzed in both groups.</div></div><div><h3>Results</h3><div>Transgender youth scored higher on the short-form scale, indicating a greater risk of ADHD, as well as on the hyperactivity/impulsivity subscale. A significant association was also found between experiences of discrimination and a prior diagnosis of depression.</div></div><div><h3>Conclusions</h3><div>The ASRS-V1.1 scale may be useful for ADHD screening in transgender individuals; however, further studies are needed to confirm these findings. Risk factors for neurodevelopmental and anxiety-depressive disorders may differ in the transgender population.</div></div>","PeriodicalId":48650,"journal":{"name":"Endocrinologia Diabetes Y Nutricion","volume":"72 8","pages":"Article 501593"},"PeriodicalIF":1.8,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145058783","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-01DOI: 10.1016/j.endien.2025.501636
Sara Ribeiro , Telma Moreno , Maria Lume , Marisa C. Couto , Diana Baptista , Conceição Souto-Moura , Ana Varela , Sandra Belo , Paula Freitas , Davide Carvalho
Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH) is a rare precursor to lung carcinoids. We report a case of ACTH-dependent Cushing's syndrome in a 73-year-old female patient with metastatic lung carcinoid arising on a background of DIPNECH. She presented with lower limb oedema, hypokalaemia, hypertension, and de novo diabetes. Clinical suspicion for hypercortisolism was confirmed by abnormal cortisol tests. A thoracic CT scan showed multiple lung nodules suggestive of DIPNECH and biopsy of one of the nodules identified an ACTH-expressing carcinoid tumour. A PET-Ga-68-DOTATOC revealed pulmonary and multiple tumour lesions in the ganglia, bone and liver with overexpression of somatostatin receptors. A liver biopsy demonstrated involvement by a well-differentiated neuroendocrine neoplasia, consistent with metastasis. Hypercortisolism was managed with octreotide and metyrapone, but the patient succumbed to complications 14 months post-diagnosis. This case suggests DIPNECH's potential to progress to hyperfunctioning, metastatic carcinoids and highlights the necessity for vigilant long-term surveillance and early intervention.
{"title":"Ectopic Cushing's syndrome in a patient with DIPNECH and metastatic lung carcinoid","authors":"Sara Ribeiro , Telma Moreno , Maria Lume , Marisa C. Couto , Diana Baptista , Conceição Souto-Moura , Ana Varela , Sandra Belo , Paula Freitas , Davide Carvalho","doi":"10.1016/j.endien.2025.501636","DOIUrl":"10.1016/j.endien.2025.501636","url":null,"abstract":"<div><div>Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH) is a rare precursor to lung carcinoids. We report a case of ACTH-dependent Cushing's syndrome in a 73-year-old female patient with metastatic lung carcinoid arising on a background of DIPNECH. She presented with lower limb oedema, hypokalaemia, hypertension, and de novo diabetes. Clinical suspicion for hypercortisolism was confirmed by abnormal cortisol tests. A thoracic CT scan showed multiple lung nodules suggestive of DIPNECH and biopsy of one of the nodules identified an ACTH-expressing carcinoid tumour. A PET-Ga-68-DOTATOC revealed pulmonary and multiple tumour lesions in the ganglia, bone and liver with overexpression of somatostatin receptors. A liver biopsy demonstrated involvement by a well-differentiated neuroendocrine neoplasia, consistent with metastasis. Hypercortisolism was managed with octreotide and metyrapone, but the patient succumbed to complications 14 months post-diagnosis. This case suggests DIPNECH's potential to progress to hyperfunctioning, metastatic carcinoids and highlights the necessity for vigilant long-term surveillance and early intervention.</div></div>","PeriodicalId":48650,"journal":{"name":"Endocrinologia Diabetes Y Nutricion","volume":"72 8","pages":"Article 501636"},"PeriodicalIF":1.8,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145236395","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-01DOI: 10.1016/j.endien.2025.501601
Francisco Javier Escalada San Martín , Irene Bretón Lesmes , Fernando Gómez Peralta , Juan Francisco Merino Torres , Francisco Pomares Gómez , Ana Chico Ballesteros , José Miguel González-Clemente , Noemí González Pérez de Villar , Cristóbal Morales Portillo , Pedro José Pinés Corrales , Wifredo Ricart Engel , M. Teresa Benedito Pérez de Inestrosa , Carlos Miranda Fernández-Santos , Ezequiel Arranz , Guadalupe Fontán Vinagre , Juan Francisco Perán , Sedisa , María Asunción Martínez Brocca
{"title":"Executive summary of the document ‘Diabetes Day Hospital. Value proposition’","authors":"Francisco Javier Escalada San Martín , Irene Bretón Lesmes , Fernando Gómez Peralta , Juan Francisco Merino Torres , Francisco Pomares Gómez , Ana Chico Ballesteros , José Miguel González-Clemente , Noemí González Pérez de Villar , Cristóbal Morales Portillo , Pedro José Pinés Corrales , Wifredo Ricart Engel , M. Teresa Benedito Pérez de Inestrosa , Carlos Miranda Fernández-Santos , Ezequiel Arranz , Guadalupe Fontán Vinagre , Juan Francisco Perán , Sedisa , María Asunción Martínez Brocca","doi":"10.1016/j.endien.2025.501601","DOIUrl":"10.1016/j.endien.2025.501601","url":null,"abstract":"","PeriodicalId":48650,"journal":{"name":"Endocrinologia Diabetes Y Nutricion","volume":"72 8","pages":"Article 501601"},"PeriodicalIF":1.8,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145058812","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号